Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial

ABSTRACT: Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial

PROVIDER: PRJNA1103250 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial

Project description:Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial

| PRJNA1103252 | ENA

Immunomodulatory effect of cisplatin and carboplatin in human and mouse cell line in vitro

Project description:The Phase 3 1L urothelial carcinoma (IMvigor130) trial revealed more favorable effects on overall survival with atezolizumab combined with gemcitabine and cisplatin (GemCis) than with atezolizumab combined with gemcitabine and carboplatin (GemCarbo). This study investigates the immunomodulatory effects of cisplatin vs carboplatin as a potential explanation for these clinical observations. GemCis compared with GemCarbo ± atezolizumab induced transcriptional changes in circulating immune cells, including upregulation of antigen presentation and T-cell activation programs. In vitro experiments demonstrated that cisplatin, compared with carboplatin, exerted direct immunomodulatory effects on cancer cells, promoting dendritic cell activation and antigen-specific T cell killing. These results underscore the key role of immune modulation in cisplatin's efficacy in urothelial carcinoma and highlight the potential importance of specific chemotherapy backbones for immune checkpoint blockade combination therapies.

2023-11-02 | GSE235066 | GEO

Project description:Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial

| PRJNA995589 | ENA

Carboplatin-mediated recovery of LPS-induced tolerant macrophages via H3K9me3 modifications

Project description:Following the re-exposure to lipopolysaccharide (LPS), macrophages exhibit the immunosuppressive state contribute to low production of proinflammatory cytokines and inability to respond the stimuli, a phenomenon is termed “tolerance”. Histone modification has been found in LPS-induced tolerant macrophages. Carboplatin, an antitumor drug, exerts its general effect on inhibition of DNA replication and transcription as well as epigenetic modification. Therefore, we hypothesized that carboplatin can be used to rescue the tolerance in macrophages. We found that carboplatin increases IL-6 but not TNF-α production in LPS-primed cells. The significant inductions were examined in carboplatin-treated tolerant macrophages evaluated by ELISA and qPCR. GSEA analyses revealed that p53 was the significant hallmark in both primed and tolerant RNA-Seq transcripts under carboplatin exposure while E2F ang G2/M were the upmost in negative hallmarks. HP1-α, heterochromatin protein 1, was significantly reduced in carboplatin-treated tolerant macrophages. The significant lower transcript of H3K9me3 methyltransferase, setdb2, was determined whereas kdm4d, demethylase encoding gene was significantly up-regulated in the presence of carboplatin in tolerant macrophages. Based on our data we suggested that carboplatin mediated upregulation of proinflammatory cytokine and rescue tolerance via the H3K9me3 modification. Carboplatin is potentially be a therapeutic drug for tolerance recovery in sepsis patients.

2021-11-10 | GSE179974 | GEO

Brucella melitensis 043

Project description:Brucella melitensis 043 Genome sequencing and assembly

| PRJNA182774 | ENA

Transcriptome profile of hepatocellular carcinoma in patients with atezolizumab plus bevacizumab therapy.

Project description:Hepatocellular carcinoma (HCC) is a rapidly increasing and highly lethal cancer worldwide, with many patients diagnosed at advanced stages and early-stage patients often experiencing high recurrence rates. The combination of atezolizumab plus bevacizumab emerged as a groundbreaking immunotherapy, establishing a new standard of care for advanced HCC. There's an urgent need for reliable biomarkers to predict patient responses and personalize treatment. We collected tumor samples from advanced HCC patients wirth atezolizumab plus bevacizumab therapy and performed comprehensive analyses of the tumor microenvironment using bulk RNA sequencing to identify key features influencing the effectiveness of atezolizumab plus bevacizumab.

2025-10-02 | GSE285963 | GEO

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Project description:This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.

| 2158476 | ecrin-mdr-crc

Vibrio parahaemolyticus strain:06-043

Project description:Vibrio parahaemolyticus 06-043 genome sequencing

| PRJNA324078 | ENA

SK-OV-3 cells under Carboplatin

Project description:SK-OV-3 cells under prolonged carboplatin exposition turn into giant cells. This dataset contains the transcriptome of cultured SK-OV-3 cells with and without carboplatin.

2016-04-30 | E-MTAB-3770 | biostudies-arrayexpress